the big surprise will be those handing over 13m to a company with no proven sales, a diluted market cap once those options get exercised of around $50m . what sort of upside can there be in this company.product will be a hard sell to doctors already using a simple procedure to do the same thing . ksx product may be an update but it will be a hard long slog to get sales to justify the current market cap.there are other medical device companies out there with sales over $40m with only half ksx's market cap. what sales margin will ksx be getting from its distributors. public relations will be working overtime to get those options exercised. my 12 month target is around 5c. better biotech stock value out there.
KSX Price at posting:
0.0¢ Sentiment: Sell Disclosure: Not Held
